

Press release March 5, 2019

Information about the ongoing exercise period for TO4.

February 22 – 8 March 2019 is exercise period of Brighter Warrants TO4 during which holders of Warrants can subscribe for shares. One (1) TO4 can be exchanged for one (1) share during the period, at a price of SEK 6.01.

In total Brighter would receive approximately SEK 77 million if all Warrants of series TO4 were to be exercised.

Holders of warrants who have their Warrants registered in custody at a bank or fund commissioner shall contact their bank or fund commissioner if they want to exercise the Warrants and subscribe for the corresponding shares.

Exercise of the Warrants and subscription of shares for other holders of Warrants takes place through simultaneous payment and submittal of the registered application form, signed and submitted to the Company's share agent (Eminova Fondkommission) no later than 16:00 CET on March 8th, 2019.

Background

As part of Brighter's historical financing strategy and the agreement with L1 Capital (finalized and terminated January 2019), the company has distributed free warrants (TO3 and TO4) to its shareholders to reduce dilution.

For terms and conditions of the Warrants, please visit: <https://brighter.se/investors/financing>

In case of need of further assistance or questions, please contact the company's share agent Eminova Fondkommission by phone (08-684 211 00) or by email (info@eminova.se).


About Brighter AB (publ).

Brighter is a Swedish-based company that, from a unique IP portfolio, creates smart solutions for one of healthcare's biggest challenges: changing patient behavior. Chronic diseases such as diabetes are rapidly increasing, and account for an increasing share of healthcare costs globally. Brighter's Business Model and Multi-Sided Market Platform - The Benefit Loop®- is based on the fact that many special interests create value for each other. By increasing access to valid health data, Brighter creates value for all stakeholders in the care chain: patients and their close associates, healthcare providers, research institutes, the pharmaceutical industry, and society as a whole. <https://brighter.se/>

The Company's shares are listed on [NASDAQOMX First North/BRIG](#).

Visit our website and subscribe to press releases: www.brighter.se

Follow us on:



www.introduce.se



Brighter AB (publ)

Norgegatan 2
SE-164 32 Kista
Sweden

+46 (0)8 550 088 20
info@brighter.se
www.brighter.se



Certified Adviser

Brighter's Certified Adviser on Nasdaq OMX First North is Eminova Fondkommission AB, +46 (0)8 – 684 211 00, info@eminova.se, www.eminova.se.

For further information, please contact:

Ann Zetterberg, CFO

Phone: +46 708 37 21 23

Email: ann.zetterberg@brighter.se



Brighter AB (publ)

Norgegatan 2
SE-164 32 Kista
Sweden

+46 (0)8 550 088 20
info@brighter.se
www.brighter.se